DGAP-News: ClariVein(R) Announces 800 Patient Randomized Trial
(firmenpresse) - Vascular Insights LLC
01.08.2012 00:00
---------------------------------------------------------------------------
RFA vs. MOCA(TM) for GSV Insufficiency
MADISON, Conn., 2012-08-01 00:00 CEST (GLOBE NEWSWIRE) --
Vascular Insights LLC. announced the start of the Maradona clinical trial
conducted by principal investigators Michel Reijnen, MD, PhD Vascular Surgeon
Rijnstate Hospital, Arnhem, The Netherlands and Jean-Paul de Vries, MD, PhD
Vascular Surgeon St. Antonius Hospital Nieuwegein, The Netherlands.
The clinical trial compares ClariVein(r) in the MOCA(tm) procedure to radio
frequency ablation (RFA) in the treatment of the great saphenous vein. This
will be a multicentre randomized clinical trial with a group of over 800
patients.
'We are very excited to start the trial, as we are confident that it will
demonstrate once again that ClariVein(r) is a game changer in the treatment of
varicose veins and venous reflux,' said John P. Marano, President of Vascular
Insights.
'For patients and physicians who demand greater patient comfort and a faster
recovery time, this study will be very impactful; we believe the final analysis
will prove that ClariVein also represents a more cost effective total solution
to venous insufficiency,' said Marano.
Dr. Michel Reijnen, principal investigator said, 'Varicose veins are a
widespread problem and the treatment has evolved to minimal invasive modalities
such as laser (EVLA) and radio frequency ablation (RFA). Both thermal
modalities, however, are related to pain and complications. The newest modality
is Mechanochemical ablation (MOCA(tm)) using the ClariVein(r) device. Initial
results are promising with a low complication rate, less pain and earlier
recovery.'
Dr. Reijnen added, 'The MARADONA trial aims to show that MOCA(tm) is associated
with: 1. Less postoperative pain in the first 14 days; 2. A comparable
complication rate; 3. A comparable short and long term occlusion rate compared
with RFA. For that purpose, 840 patients will be included in a large randomized
trial in the Netherlands.'
Data will be collected at 4 weeks, 1 year, 2 years and 5 years as patients are
seen on the outpatient clinic to observe the clinical success after treatment
objectively.
The ClariVein(r) catheter is a product of Vascular Insights LLC
(http://vascularinsights.com) of Madison, Connecticut USA. The company engages
in the design, development, manufacture, and marketing of medical devices for
the minimally invasive treatment of peripheral vascular disease.
The investigators anticipate presenting data in early 2013.
The Vascular Insights LLC logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13814
Joseph Mullally
Director of International Sales
Vascular Insights LLC
j.mullally(at)vascularinsights.com
203 446 5709
News Source: NASDAQ OMX
01.08.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Vascular Insights LLC
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901942279
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.08.2012 - 00:00 Uhr
Sprache: Deutsch
News-ID 170457
Anzahl Zeichen: 4713
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 357 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: ClariVein(R) Announces 800 Patient Randomized Trial"
steht unter der journalistisch-redaktionellen Verantwortung von
Vascular Insights LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
